PRESS RELEASE published on 09/05/2024 at 07:30, 2 years ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 08/20/2024 at 17:52, 2 years ago Terms of participation in the Medincell General Meeting Shareholders General Assembly Remote Voting Medincell Videoconference
PRESS RELEASE published on 08/20/2024 at 17:47, 2 years ago Terms of availability of the preparatory documents for the GM Medincell announces participation terms in the Combined General Meeting on September 12, 2024, including remote voting options, video conference for shareholders, and document availability Shareholders Combined General Meeting Remote Voting Medincell Participation Terms
BRIEF published on 06/28/2024 at 07:35, 2 years 2 months ago H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation FDA Approval BUY Rating Biopharmaceuticals H.C. Wainwright & Co. Medincell
PRESS RELEASE published on 06/28/2024 at 07:30, 2 years 2 months ago Inside Information / Other news releases H.C. Wainwright & Co. initiates coverage of MedinCell with a 'Buy' recommendation at €24 price target, reflecting +80% potential increase. MedinCell achieves milestones with FDA approvals, positive Phase 3 results, and collaboration with AbbVie FDA Approval Coverage Initiation H.C. Wainwright & Co. Medincell Pharmaceutical Sector
BRIEF published on 06/11/2024 at 09:05, 2 years 3 months ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 2 years 3 months ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 2 years 4 months ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
BRIEF published on 05/08/2024 at 12:35, 2 years 4 months ago Positive Results for the SOLARIS Phase 3 Trial of Olanzapine Schizophrenia Medincell SOLARIS Olanzapine TEV-'749
PRESS RELEASE published on 05/08/2024 at 12:30, 2 years 4 months ago Inside Information / Other news releases Teva and Medincell announce positive Phase 3 efficacy results from SOLARIS trial evaluating TEV-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia Schizophrenia Medincell Teva Phase 3 Efficacy Results SOLARIS Trial
Published on 09/16/2026 at 16:55, 58 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 2 hours 53 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 3 hours 53 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 13:30, 4 hours 23 minutes ago Sterling Extends Core MEPS Copper Zone to 700m; Intersects 200m of 0.53% CuEq Including 102m of 0.81% CuEq
Published on 09/16/2026 at 13:23, 4 hours 30 minutes ago SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 17:35, 17 minutes ago M&G Credit Income Investment Trust plc: Net Asset Value(s)
Published on 09/16/2026 at 17:30, 23 minutes ago MP-14 ORIGIN BY JEFF KOONS - KOONS × HUBLOT: TWO UNIVERSES BUILT ON TRANSFORMATION
Published on 09/16/2026 at 17:20, 32 minutes ago HUBLOT - CLASSIC FUSION BALLOON DOG BY JEFF KOONS: TIME, INFLATED INTO ART
Published on 09/16/2026 at 17:15, 38 minutes ago Hong Kong’s 2026 Policy Address: A Strategic Vision for a Bright New Era
Published on 09/16/2026 at 17:45, 8 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 10 hours 53 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 23 hours 53 minutes ago Report on the Combined General Meeting of the 10th of September 2026
